

Haematologica
HAEMATOL/2019/224535
Version 4

Clinical activity of abemaciclib in patients with relapsed or refractory
mantle cell lymphoma - a phase II study

Franck Morschhauser, Kamal Bouabdallah, Stephan Stilgenbauer,
Catherine Thieblemont, Sophie de Guibert, Florian Zettl, Lawrence M.
Gelbert, P. Kellie Turner, Siva Rama Prasad Kambhampati, Li Li, Lily
Q. Li, Sean Buchanan, Susana Barriga, Melissa M. Bear, Martin
Wilhelm, and Georg Hess

Disclosures: Dr. Morschhauser reports personal fees from Celgene, Roche, Gilead, Epizyme, Janssen, BMS and Bayer outside the submitted work. Dr. Bouabdallah has nothing to disclose. Dr. Stilgenbauer has received grants from AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffman La-Roche, Janssen, Novartis, Pharmacyclics and Sunesis outside the submitted work; has received personal fees from AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffman La-Roche, Janssen, Novartis, Pharmacyclics and Sunesis outside the submitted work; has received non-financial support from AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffman La-Roche, Janssen, Novartis, Pharmacyclics and Sunesis outside the submitted work. Dr. Thieblemont has received personal fees from AstraZeneca, Gilead, Novartis, Roche, Janssen, Cellectis, Bayer. Dr. De Guibert has nothing to disclose. Dr. Zettl has nothing to disclose. Dr. Gelbert is a co-inventor of abemaciclib. Dr. Turner is a full-time employee and shareholder of Eli Lilly and Company, the sponsor of the work. Dr. Kambhampati was an employee of Eli Lilly and Company at the time this study was conducted. Dr. Li Li is a full-time employee and stock shareholder of Eli Lilly and Company, the sponsor of the work. Dr. Lily Q. Li is a full-time employee and stock shareholder of Eli Lilly and Company, the sponsor of the work. Dr. Buchanan is a full-time employee and stock shareholder of Eli Lilly and Company, the sponsor of the work. Dr. Barriga is a full-time employee and stock shareholder of Eli Lilly and Company, the sponsor of the work. Dr. Bear was a full-time employee and stock shareholder of Eli Lilly and Company, the sponsor of the work. Dr. Wilhelm has nothing to disclose. Dr. Hess has received grants from Pfizer, Celgene, Roche and Morphosys; has received personal fees from Janssen, Celgene, Roche, Gilead, Morphosys and Novartis outside the submitted work.

Contributions: Conception of the work - FM, FZ, LMG Design of the work - FM, Lily Li Data acquisition for the work- FM, KB, SS, CT, SDG, FZ, PKT, MW, GH Data analysis for the work- FM, SS, CT, PKT, SRPK, Li Li, Lily Li, SB, SB Data interpretation for the work - FM, MB, SS, CT, PKT, Lily Li, SB, MW, GH, SB Drafting of the work - SDG, LMG, PKT, SRPK, SB Critical revision of the work - FM, KB, SS, CT, FZ, PKT, Li Li, Lily Li, SB, MB, MW, GH, SB